Business Wire

Global Survey Reveals Urgency to Accelerate Study Start-up

Share

Accelerating study start-up is a top priority for life sciences companies according to the Veeva 2020 Study Start-up Pulse Report & Assessing Post-COVID Readiness, a global study start-up survey of more than 500 clinical operations professionals. Findings from Veeva Systems (NYSE: VEEV) show an industrywide shift to streamline study activation and speed clinical trials.

While there is an overall move underway in life sciences to modernize trial execution, COVID-19 has prompted an even greater need to keep existing trials on track and get new studies up and running faster. This research reveals that study start-up is an area of significant potential to speed trials, which is especially timely as sponsors and CROs ready for a major wave of post COVID-19 trial starts.

All sponsors and CROs surveyed report the need to improve study start-up. Nearly all (98%) have significant challenges, many stemming from delays in the first steps to launch trials. Top drivers for improving study start-up are accelerated start-up times (75%) and reduced manual processes (53%). The majority say automating activities such as contracting and budgeting, and site essential document collection can positively impact trial quality and speed.

A heavy reliance on applications that are not fit for purpose are slowing trials. The majority (81%) use spreadsheets to manage study start-up and roughly half use other applications that are not purpose-built for this area, like eTMF and CTMS.

Most sponsors and CROs use a combination of spreadsheets and multiple applications—not only slowing study starts, but also creating system and process siloes. The more tools used, the greater number of study start-up challenges companies report. The industry, however, is taking action as a quarter of respondents are adopting study start-up applications to streamline trials.

“Study activation is one of the most time and resource-intensive areas of drug development, so companies are working hard to eliminate start-up delays and minimize downstream risks to study milestones,” said Ashley Davidson, senior director, Veeva Vault Study Startup. “This is especially important as the industry races to get trial timelines back on track that have been disrupted by COVID-19.”

The Veeva 2020 Study Start-up Pulse Report explores the life sciences industry’s progress towards streamlining study start-up by gathering the experiences and opinions of more 500 clinical operations professionals around the globe. The goal of the research is to understand the drivers, barriers, and benefits of modernizing clinical systems and processes to accelerate trials and gives an industrywide view of study start-up technology adoption. Get the full report at veeva.com/eu/StudyStartupReport.

Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 875 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.

Contact information

Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com

Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wintershall Dea and Cognite Enable Domain Experts to Harness Value From Data in the North Sea21.9.2020 11:50:00 CESTPress release

In a continued commitment to drive value through digital, Wintershall Dea has agreed with Cognite to deploy Cognite Data Fusion (CDF) to Brage, scaling the Wintershall Dea Data Hub from Germany to Norway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005336/en/ This effort builds on an existing partnership between the companies. It will allow the ingestion and contextualization of data from the Brage field to build applications which support Wintershall Dea domain experts in decision-making for smart maintenance and production optimization. An advisory tool to enable dynamic separator capacity limits will be developed to support decisions related to production optimization, thereby increasing throughput & reduced OPEX. Safety optimization for critical valves will be achieved by moving from calendar-based maintenance to proactive maintenance, by using contextualized data from valves and other safety-critical equipment.

Sagemcom AMI Solution, a Key Driver in the Swedish Energy Transition to a Sustainable Future21.9.2020 10:30:00 CESTPress release

In September, ELLEVIO will continue to improve the Swedish electricity system by being one the first Nordic DSO to start its 2nd generation smart meters large scale rollout. This massive rollout is the result of joint achievements between ELLEVIO, Sagemcom and its local Partner, ONE Nordic. Since the award in March 2019, Sagemcom has developed and delivered a new generation of S211 single phase meters and T211 polyphase meters which allow ELLEVIO to take up the new energy landscape and customer care. The advanced deep indoor dual cellular technology LTE NB IoT + LTE Cat-M is used to secure the reliability of the solution. In less than 8 months and within a specific context, Sagemcom has developed and certified the new generation of smart meters which are installed in the field by ONE Nordic since June 2020 in Stockholm area. The new key features have already been deployed offering a combination of end-user experience - through a customer local interface (P1 Port) - and Low-Voltage netw

Market Failure? kENUP and YUVEDO High-Level Online Event Kick-starts Call for Projects Tackling the Growing Threat of Parkinson’s and Other Neurodegenerative Diseases .21.9.2020 10:14:00 CESTPress release

On Friday, 18 September 2020, YUVEDO Foundation and kENUP Foundation held a high-level online conference to kick-start an open public call for projects tackling the growing threat of Parkinson’s (PD) and other neurodegenerative diseases (NDD). Despite the predictable medical, social and economic challengesof NDDs, too little has happened in recent years to address the underlying causes of NDDs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005283/en/ Market and Regulatory Failure? High-Level Online Conference Kick-starts Open Public Call for Projects Tackling the Growing Threat of Parkinson’s and Other Neurodegenerative Diseases (Photo: Business Wire) An expert report by Professor Maier-Rigaud of NERA Economic Consulting presented at the conference, showed that there are indications for market and regulatory failure around the development of interventions against PD and other NDDs: High risk in product development is

PMI Announces Keynote Speeches at International Forums During UN General Assembly21.9.2020 10:00:00 CESTPress release

MEDIA ADVISORY: Philip Morris International Inc. (PMI) (NYSE: PM) today announced its participation in a series of events over the course of the United Nations General Assembly. Senior executives, including PMI’s CEO André Calantzopoulos and COO Jacek Olczak, will address international forums to talk about the critical role that science can play in driving innovation, progress, and policy to tackle the most pressing global issues. Keynote virtual events include: September 21: PMI COO Jacek Olczak is joining the Diplomatic Courier’s “The SDG’s in Action Forum”discussing “Industry, Infrastructure and Innovation” September 23: Silke Muenster, Chief Diversity Officer, will address The Hill’s “Work Defined” virtual event September 24:PMI CEOAndré Calantzopoulos will present high-level remarks during the 2020 Concordia Annual Summitexploring “Leading Industry Transformation with Purpose” September 29: André Calantzopoulos will be a panelist in a custom event with Dow Jones' The Trust on “Mul

Thales Empowers Organisations to Simplify the Discovery, Protection and Control of Sensitive Data21.9.2020 09:00:00 CESTPress release

Thales today announced the launch of the CipherTrust Data Security Platform, the industry’s first unified data protection solution that enables organisations to discover, protect, and control their most sensitive data wherever it resides. The new platform helps solve key challenges they face today. These include data security complexity caused by multi-cloud adoption, evolving global and regional privacy regulations, as well as the risk of data breaches from external and internal threats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005046/en/ Copyright Thales Drawing from years of data protection innovation, Thales has built the CipherTrust Data Security Platform to seamlessly unify data discovery, classification and data protection, along with strong access controls and centralised key management. The ‘all-in-one’ platform combines the best of Thales’s Vormetric and SafeNet KeySecure technologies to give organisati

Inflazome Announces Acquisition by Roche21.9.2020 08:00:00 CESTPress release

Inflazome announced today that it has closed a share purchase agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) in which Inflazome’s shareholders received an upfront payment of €380 million, and are eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones. Inflazome was founded in 2016 by leading medical researchers Prof Matt Cooper (University of Queensland, Australia) and Prof Luke O’Neill (Trinity College Dublin, Ireland). The company is a leader in the development of inflammasome inhibitors. The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors. Roche intends to further develop NLRP3 inhibitors across a wide variety of indications with high unmet medical need. Matt Cooper, Chief Executive Officer, Inflazome, commented: “We are delighted to close this deal with Roche, an outstanding pharmaceutical company w